蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1313|回复: 4
收起左侧

【讨论】FDA: More Inspections in India

[复制链接]
药徒
发表于 2014-3-10 16:34:34 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x

In her monthly blog, FDA Commissioner Margaret A. Hamburg gives a personal overview about her recent visit in India. The Federation of Indian Chambers of Commerce and Industries organised roundtable meetings where challenges of Indian pharmaceutical and food exporting companies were discussed. More and more generics are produced in India and quite a few abbreviated new drug applications (ANDA) in the U.S. are still waiting for approval. Margaret A. Hamburg said that FDA is working on reducing the current backlog of generic drug applications. The Generic Drug User Fee Act (GDUFA) supports these actions but does also require and fund more foreign inspections. Companies participating in the roundtable meetings said "they were challenged by our heightened inspectional activities" but Hamburg emphasised that "every company supplying the U.S. market has the responsibility of ensuring that their products are safe, effective and of high-quality".
"In recent years the FDA has identified significant lapses in quality by some companies operating in the U.S. and around the world.", Hamburg said. "This is unacceptable. Consumers should be confident that the products they are using are safe and high quality and when companies sacrifice quality, putting consumers at risk, they must be held accountable."
回复

使用道具 举报

发表于 2014-3-10 16:41:48 | 显示全部楼层
好人大爆发啊?
回复

使用道具 举报

药生
发表于 2014-3-10 16:49:35 来自手机 | 显示全部楼层
好吧,虽然我不赞成直接拷贝粘贴
回复

使用道具 举报

药徒
发表于 2014-3-10 16:53:45 | 显示全部楼层
进入美国市场印度比我们要更理解如何操作。美国可能要加快和打开紧闭的大门,我们向着美国鬼子冲呀
回复

使用道具 举报

发表于 2014-3-10 17:55:36 | 显示全部楼层
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-6-25 00:46

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表